(Total Views: 387)
Posted On: 03/14/2019 2:32:36 PM
Post# of 72443
I believe this is new information. They never disclosed this information before. We knew about the meeting. We didn't know the results
In December, Innovation Pharmaceuticals completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), during which an acceptable Phase 3 development pathway was agreed upon to advance Brilacidin.
In December, Innovation Pharmaceuticals completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), during which an acceptable Phase 3 development pathway was agreed upon to advance Brilacidin.
(0)
(0)Scroll down for more posts ▼
